ADAM17 and non-small cell lung carcinoma: The limited number of studies investigating ADAM17 in NSCLC has suggested that elevated ADAM17 expression correlates with numerous clinicopathological characteristics (e.g., tumor grade) and poor survival (Ni et al, 2013).